

Philip L. McCarthy, MD  
Professor of Oncology & Internal Medicine  
Chief, BMT Program  
Department of Medicine at Roswell Park Cancer Institute/SUNY at Buffalo

My research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. I have over 25 years of experience treating patients with hematologic disorders, directing clinical and translational studies with a particular interest in multiple myeloma (MM). I have served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous HSCT for MM. This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after autologous HSCT. Our team has developed a systematic approach to the evaluation and treatment of HSCT patients with a specific focus on minimizing treatment-related mortality (TRM) and predicting outcome. We participate with a core group of basic science and clinical researchers who are committed to developing novel approaches to improve outcomes.